ERBB2 and breast cancer: Thus, in HER2/ERBB2-driven breast cancer, hypoxia-induced HIF-1 promotes HER2 inhibitor lapatinib resistance via inhibiting MAPK phosphatase dual-specificity phosphatase (DUSP2) expression, thereby compensating the loss of MAPK activity in lapatinib-treated cells [82].